Last $4.81 USD
Change Today +0.01 / 0.21%
Volume 54.3K
PSDV On Other Exchanges
Symbol
Exchange
NASDAQ GM
Stuttgart
Frankfurt
OTC US
As of 12:09 PM 08/28/14 All times are local (Market data is delayed by at least 15 minutes).

psivida corp (PSDV) Snapshot

Open
$4.75
Previous Close
$4.80
Day High
$4.88
Day Low
$4.72
52 Week High
10/2/13 - $5.60
52 Week Low
10/31/13 - $2.28
Market Cap
140.7M
Average Volume 10 Days
201.0K
EPS TTM
$-2.26
Shares Outstanding
29.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PSIVIDA CORP (PSDV)

psivida corp (PSDV) Related Businessweek News

No Related Businessweek News Found

psivida corp (PSDV) Details

pSivida Corp. develops products to deliver drugs and biologics primarily in the United States and the United Kingdom. The company, through its Durasert and BioSilicon technology platforms, focuses on the treatment of chronic diseases of the back of the eye. It offers ILUVIEN, an injectable sustained-release micro-insert delivering fluocinolone acetonide for the treatment of vision impairment associated with chronic diabetic macular edema; and Retisert for the treatment of posterior uveitis. The company’s ILUVIEN is also studied in two Phase II clinical trials for the treatment of the dry form of age-related macular degeneration and retinal vein occlusion. It also develops Medidur, which is in Phase III clinical trials for the treatment of posterior uveitis; TBD that is in Phase I/II clinical trial for the treatment of glaucoma; and glaucoma latanoprost product candidate, which is an injectable bioerodible drug delivery micro-insert for the treatment of glaucoma and ocular hypertension. The company has strategic collaborations with Alimera Sciences, Inc.; Pfizer, Inc.; Bausch & Lomb Incorporated; Intrinsiq Materials Cayman Limited; and Enigma Therapeutics Limited. pSivida Corp. was founded in 1987 and is headquartered in Watertown, Massachusetts.

25 Employees
Last Reported Date: 09/27/13
Founded in 1987

psivida corp (PSDV) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: $728.3K
Principal Financial & Accounting Officer and ...
Total Annual Compensation: $302.7K
Vice President of Corporate Affairs, General ...
Total Annual Compensation: $466.4K
Compensation as of Fiscal Year 2013.

psivida corp (PSDV) Key Developments

pSivida Corp. Announces Iluvien Receives Marketing Authorization from Danish Health and Medicines for the Treatment of Vision Impairment

pSivida Corp. reported that the Danish Health and Medicines Authority granted marketing authorization to Iluvien for the treatment of vision impairment associated with chronic diabetic macular edema considered insufficiently responsive to available therapies. Iluvien has now been approved in nine EU countries, and is commercially available in the United Kingdom and Germany. Iluvien is in the national phase, pending approval, in eight more EU countries following the successful completion of the Mutual Recognition Procedure for subsequent marketing authorizations. Iluvien is currently under review by the U.S. Food and Drug Administration with a Prescription Drug User Fee Act goal date of September 26.

pSivida Corp. Announces ILUVIEN(R) Receives Marketing Authorization in Norway and Approval for Reimbursement in Portugal

pSivida Corp. announced that ILUVIEN(R) has been has granted marketing authorization in Norway for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies and has been approved for reimbursement in Portugal for the same indication. The Norway marketing authorization is the first following the successful completion last month of the Mutual Recognition Procedure for Norway and nine other EU countries. Marketing authorization is pending in the remaining nine countries. ILUVIEN has been approved for reimbursement in Portugal by INFARMED, the marketing authorization body of the Portuguese Ministry of Health. Alimera has reported it plans to move forward with commercialization in Portugal in late 2014. ILUVIEN is commercially available in the U.K. and Germany and has marketing authorization in Austria, Portugal, France, Spain and Italy. ILUVIEN is currently under review by the U.S. Food and Drug Administration with a Prescription Drug User Fee Act (PDUFA) goal date of September 26, 2014.

Italian Medicines Agency Grants Marketing Authorization to ILUVIEN of pSivida Corp. for the Treatment of Vision Impairment

pSivida Corp. announced that the Italian Medicines Agency (Agenzia Italiana del Farmaco) has granted marketing authorization to ILUVIEN(R) for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies. The ILUVIEN marketing authorization notice was published on June 18 in the Gazzetta Ufficiale della Repubblica Italiana, the official journal of record of the Italian government. Designated a C Class product in Italy, ILUVIEN will be available initially to private paying patients, and pSivida's licensee, Alimera Sciences, is pursuing H Class designation for ILUVIEN with the Italian regulatory authorities, which, if granted, would expand patient access to the product. The Italian authorization marks the seventh national approval in the EU. ILUVIEN is authorized in Austria, the United Kingdom, Portugal, France, Germany and Spain and is commercially available in the U.K. and Germany. Alimera is also engaged in a Repeat Use Procedure through Mutual Recognition (MRP) to obtain a positive opinion for approval from another 10 EU countries. In the United States, ILUVIEN is awaiting a decision from the FDA on the refiled NDA, with a Prescription Drug User Fee Act (PDUFA) goal date of September 26, 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PSDV:US $4.81 USD +0.01

PSDV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Allergan Inc/United States $163.48 USD +0.72
Novartis AG SFr.82.00 CHF -0.30
Regeneron Pharmaceuticals Inc $348.23 USD -1.78
View Industry Companies
 

Industry Analysis

PSDV

Industry Average

Valuation PSDV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 36.2x
Price/Book 7.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 32.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PSIVIDA CORP, please visit www.psivida.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.